Bendroflumethiazide

Bendroflumethiazide
Clinical data
AHFS/Drugs.comConsumer Drug Information
Pregnancy
category
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability100%
Protein binding96%
Metabolismextensive
Elimination half-life3-4 hours[2]
Identifiers
  • 3-Benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4- benzothiadiazine-7-sulfonamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.728 Edit this at Wikidata
Chemical and physical data
FormulaC15H14F3N3O4S2
Molar mass421.41 g·mol−1
3D model (JSmol)
  • FC(F)(F)c3c(cc1c(NC(NS1(=O)=O)Cc2ccccc2)c3)S(=O)(=O)N
  • InChI=1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23) checkY
  • Key:HDWIHXWEUNVBIY-UHFFFAOYSA-N checkY
  (verify)

Bendroflumethiazide, formerly bendrofluazide, trade name Aprinox, is a thiazide diuretic used to treat hypertension.

Bendroflumethiazide is a thiazide diuretic which works by inhibiting sodium reabsorption at the beginning of the distal convoluted tubule (DCT). Water is lost as a result of more sodium reaching the collecting ducts. Bendroflumethiazide has a role in the treatment of mild heart failure although loop diuretics are better for reducing overload. The main use of bendroflumethiazide currently is in hypertension (part of the effect is due to vasodilation).

It was patented in 1958 and approved for medical use in 1960.[3]

Adverse effects

Common adverse effects:[4]

Rare adverse effects:[5]

Alcohol

Bendroflumethiazide is known to have an adverse interaction with alcohol. It is advised that those using this diuretic should abstain from alcohol consumption during use, as it is possible to experience a sudden drop in blood pressure, especially if standing up (an effect known as orthostatic hypotension).

Other considerations

Bendroflumethiazide should not be used by pregnant women, or women who have just given birth. Due to the nature of the medication, it is possible for it to pass into the breast milk and consequently to the child. It is also known that bendroflumethiazide suppresses the production of breast milk. Pregnant or lactating women with hypertension may need to discuss with their prescriber as to which alternative treatment may be more suitable. Bendroflumethiazide may also impair the user's motor skills, therefore it is important to be aware of its effects and to take caution when operating machinery of driving.[4]

References

  1. ^ BNF 45 March 2003
  2. ^ Ed. Sean C. Sweetman (ed.). Martindale: The complete drug reference (33 ed.). Pharmaceutical Press.
  3. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 456. ISBN 9783527607495.
  4. ^ a b "Bendroflumethiazide". NHS. 29 August 2018. Retrieved 2018-09-29.
  5. ^ "Bendroflumethiazide Side Effects". Drugs.com. Retrieved 2018-09-29.